CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Completed
Trial Phase
Phase 1/2
Enrollment
220 patients (estimated)
Sponsors
Bristol Myers Squibb
Tags
Cereblon E3 Ligase Modulators (CELMoDs)
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1319
NCT Identifier
NCT05372354

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.